The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia-Reference-Cited by-同舟云学术

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Published:2018-06-14 Issue:24 Volume:131 Page:2661-2669
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Stein Eytan M.¹,Garcia-Manero Guillermo²,Rizzieri David A.³,Tibes Raoul⁴,Berdeja Jesus G.⁵,Savona Michael R.⁶,Jongen-Lavrenic Mojca⁷,Altman Jessica K.⁸,Thomson Blythe⁹,Blakemore Stephen J.⁹,Daigle Scott R.⁹,Waters Nigel J.⁹,Suttle A. Benjamin⁹,Clawson Alicia⁹,Pollock Roy⁹,Krivtsov Andrei¹⁰,Armstrong Scott A.¹⁰,DiMartino Jorge¹¹,Hedrick Eric⁹,Löwenberg Bob⁷,Tallman Martin S.¹

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY;

2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;

3. Duke University Medical Center, Durham, NC;

4. Mayo Clinic Scottsdale Arizona, Scottsdale, AZ;

5. Sarah Cannon Research Institute, Nashville, TN;

6. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN;

7. Erasmus University Medical Center, Rotterdam, The Netherlands;

8. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL;

9. Epizyme, Inc., Cambridge, MA;

10. Dana-Farber Cancer Institute, Boston, MA; and

11. Celgene, San Francisco, CA

Abstract

Key Points Pinometostat demonstrates first evidence of DOT1L target inhibition and clinical responses in a subset of MLL-r advanced leukemia patients. The observed safety profile of pinometostat shows potential for exploration of combination therapies in leukemia.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/24/2661/1469179/blood818948.pdf

Reference35 articles.

1. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases;Schoch;Blood,2003

2. Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11q23 abnormalities;Garrido;Leuk Res,2000

3. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461);Byrd;Blood,2002

4. MLL translocations, histone modifications and leukaemia stem-cell development;Krivtsov;Nat Rev Cancer,2007

5. Secondary leukemias induced by topoisomerase-targeted drugs;Felix;Biochim Biophys Acta,1998

Cited by 340 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological Relevance of Dual Lysine and N-Terminal Methyltransferase METTL13;Biomolecules;2024-09-03

2. Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HATs as anti-leukemia agents;Bioorganic Chemistry;2024-09

3. DOT1L-mediated RAP80 methylation promotes BRCA1 recruitment to elicit DNA repair;Proceedings of the National Academy of Sciences;2024-08-22

4. RNA sequestration in P-bodies sustains myeloid leukaemia;Nature Cell Biology;2024-08-21

5. Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia;Biomedicines;2024-08-06